Physics / mechanism
Enzymatic and chemical DNA synthesis builds oligonucleotides base-by-base from phosphoramidite monomers (chemical) or engineered polymerases (enzymatic). Chemical synthesis (phosphoramidite) dominates: ~99.5% per-step coupling efficiency, but error rates compound—200-mer accuracy degrades to ~37% error-free strands without correction. Twist Bioscience uses silicon-based high-density microwell arrays (1M+ synthesis clusters per wafer) to drive cost toward $0.005/bp. Ansa Biotechnologies uses terminal deoxynucleotidyl transferase (TdT) for template-free enzymatic synthesis, targeting longer oligos (500–1000+ bp) with fewer error accumulation issues. Telesis Bio (Gibson-licensed) offers enzymatic gene assembly. Key competitive parameters: cost per base pair, error rate, max oligo length, turnaround time, throughput.
Competitive landscape
Chemical synthesis hits a hard length ceiling (~200 bp) due to cumulative coupling failure. Enzymatic approaches promise 1000+ bp but aren’t yet at commercial parity on cost or throughput. Twist is structurally advantaged as a semiconductor-style manufacturer—fixed silicon tooling, volume scaling, fab-like capex moats. Competitors include IDT (Danaher), Integrated DNA Technologies, Genscript, and Evonetix (UK, thermal array-based). Adjacent: cell-free protein expression, Gibson assembly reagents, CRISPR delivery vectors. The real adjacency battle is who owns the full stack from synthesis to sequence-verified, ready-to-clone constructs.
Companies using
Connected ideas
Sources
Frontier (open questions)
- To be added.